why choose us

300×250 Ad Slot

Drug FDA Status

Showing 90 of 161 result(s) (Page 9 of 17)
Drug Name: Nemluvio

Active Ingredient: nemolizumab-ilto

Approval Date: 2024-08-12

Description: To treat prurigo nodularis
Drug Trials Snapshot

Drug Name: Yorvipath

Active Ingredient: palopegteriparatide

Approval Date: 2024-08-09

Description: To treat hypoparathyroidism
Drug Trials Snapshot

Drug Name: Voranigo

Active Ingredient: vorasidenib

Approval Date: 2024-08-06

Description: To treat Grade 2 astrocytoma or oligodendroglioma
Drug Trials Snapshot

Drug Name: Leqselvi

Active Ingredient: deuruxolitinib

Approval Date: 2024-07-25

Description: To treat severe alopecia areata
Drug Trials Snapshot

Drug Name: Kisunla

Active Ingredient: donanemab-azbt

Approval Date: 2024-07-02

Description: To treat Alzheimer’s disease
Drug Trials Snapshot

Drug Name: Ohtuvayre

Active Ingredient: ensifentrine

Approval Date: 2024-06-26

Description: To treat chronic obstructive pulmonary disease
Drug Trials Snapshot

Drug Name: Piasky

Active Ingredient: crovalimab-akkz

Approval Date: 2024-06-20

Description: To treat paroxysmal nocturnal hemoglobinuria
Drug Trials Snapshot

Drug Name: Sofdra

Active Ingredient: sofpironium

Approval Date: 2024-06-18

Description: To treat primary axillary hyperhidrosis
Drug Trials Snapshot

Drug Name: Iqirvo

Active Ingredient: elafibranor

Approval Date: 2024-06-10

Description: To treat primary biliary cholangitis in combination with ursodeoxycholic acid
Drug Trials Snapshot

Drug Name: Rytelo

Active Ingredient: imetelstat

Approval Date: 2024-06-06

Description: To treat low- to intermediate-1 risk myelodysplastic syndromes
Drug Trials Snapshot

300×250 Ad Slot